Back

Mechanotherapeutic Potential of Survivin in Glioblastoma

Inserra, G.; Balghonaim, S.; Jong, J.; Drewes, R.; Santo, B. A.; Tumenbayar, B.-I.; Pham, K.; Babatunde, S.; Tomaszewski, J. E.; Ignatowski, T. A.; Zhao, R.; Lim, J.; Kim, S.; Siddiqui, A. H.; Das, B. C.; Tutino, V. M.; Bae, Y.

2026-03-20 pathology
10.64898/2026.03.18.712467 bioRxiv
Show abstract

Glioblastoma Multiforme (GBM) is a highly aggressive brain cancer characterized by rapid proliferation and extensive remodeling of the extracellular matrix (ECM), leading to progressive tissue stiffening. Although ECM stiffness is known to promote GBM progression, the molecular mechanisms linking mechanical cues to tumor growth remain insufficiently defined. In this study, transcriptomic comparison of GBM tumors and non-neoplastic brain tissue revealed coordinated upregulation of cell cycle regulators and matrisome-associated genes, with survivin (BIRC5) identified as a central node linking proliferative signaling and ECM remodeling networks. Analysis of GBM patient specimens further showed strong nuclear survivin expression in regions with elevated collagen deposition. To directly evaluate stiffness-dependent regulation of survivin, GBM cells were cultured on fibronectin-infused hydrogels with tunable stiffness. Stiff matrices increased survivin expression along with cyclin D1 and cyclin A, consistent with increased cell cycle progression. Pharmacologic inhibition or siRNA-mediated suppression of survivin reduced stiffness-induced proliferation and attenuated expression of matrisome components, including collagens and lysyl oxidase. These findings indicate that survivin functions as a mechanosensitive regulator that coordinates cell cycle progression with ECM production in stiff tumor microenvironments. Collectively, this study identifies survivin as a key mediator linking ECM stiffness to GBM growth and matrisome remodeling. Targeting survivin and its effectors may offer a mechanosensitive strategy to limit GBM growth.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
JCI Insight
241 papers in training set
Top 0.1%
23.0%
2
Brain
154 papers in training set
Top 0.8%
7.0%
3
Advanced Science
249 papers in training set
Top 2%
6.5%
4
Cell Reports
1338 papers in training set
Top 14%
3.7%
5
PLOS ONE
4510 papers in training set
Top 38%
3.7%
6
Clinical Cancer Research
58 papers in training set
Top 0.7%
2.4%
7
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 29%
1.9%
8
Scientific Reports
3102 papers in training set
Top 52%
1.9%
50% of probability mass above
9
Nature Communications
4913 papers in training set
Top 48%
1.9%
10
Cancer Research
116 papers in training set
Top 2%
1.9%
11
Acta Neuropathologica Communications
81 papers in training set
Top 0.5%
1.8%
12
Cell Reports Medicine
140 papers in training set
Top 3%
1.7%
13
iScience
1063 papers in training set
Top 14%
1.7%
14
Neoplasia
22 papers in training set
Top 0.2%
1.7%
15
The American Journal of Pathology
31 papers in training set
Top 0.2%
1.7%
16
Cancers
200 papers in training set
Top 3%
1.7%
17
Cancer Letters
32 papers in training set
Top 0.3%
1.5%
18
Journal of Biological Chemistry
641 papers in training set
Top 2%
1.4%
19
Journal of Clinical Investigation
164 papers in training set
Top 4%
1.4%
20
Science Translational Medicine
111 papers in training set
Top 3%
1.4%
21
mBio
750 papers in training set
Top 9%
1.3%
22
Frontiers in Microbiology
375 papers in training set
Top 7%
1.0%
23
Experimental Neurology
57 papers in training set
Top 1.0%
1.0%
24
Modern Pathology
21 papers in training set
Top 0.3%
0.9%
25
Neuro-Oncology Advances
24 papers in training set
Top 0.4%
0.9%
26
Cell Death & Disease
126 papers in training set
Top 2%
0.8%
27
PLOS Pathogens
721 papers in training set
Top 8%
0.8%
28
Cell Communication and Signaling
35 papers in training set
Top 1%
0.8%
29
eLife
5422 papers in training set
Top 57%
0.8%
30
The Journal of Pathology
22 papers in training set
Top 0.4%
0.8%